India Glycols Q2 & H1 FY26 Earnings Call Transcript
India Glycols Limited released the transcript of its Q2 & H1 FY26 earnings conference call, reporting revenue and profit growth across various segments, including biofuels and potable spirits.
The financial results indicate stable growth and profitability. The preferential allotment and debt reduction plans suggest a positive financial strategy.
The announcement contains positive financial results for Q2 and H1 FY26, including revenue and profit growth, along with positive future expectations.
* India Glycols Limited's Q2 & H1 FY26 earnings conference call transcript is now available. * Q2 FY26: Gross revenues increased by 13% to ₹2,412 crore, net revenue up 14% to ₹1,092 crore, EBITDA up 33% to ₹160 crore, and PAT up 31% to ₹65 crore. * H1 FY26: Gross revenues increased by 11% to ₹4,916 crore, net revenue up 11% to ₹2,133 crore, EBITDA up 25% to ₹311 crore, and PAT up 26% to ₹138 crore. * Biofuels sales increased by 63% to ₹423 crore for the quarter and 54.5% to ₹770 crore for H1. * Potable Spirits sales up by 24.5% to ₹338 crore for the quarter and 23.4% to ₹338 crore for H1. * Chemicals business sales were ₹288 crore for the quarter. * Biofuels EBIT margins increased from 5.1% to 6.9%, Potable Spirits from 20.5% to 21.4%, and Chemicals from 8.1% to nearly 11% for Q2. * Management expects the excise policies to be in their favor for '26-'27. * The board approved the issuance of ₹467 crore equity to promoters, friends, and relatives at ₹915, which has been approved in the EGM. The funds will be used for term loan reduction. * India Glycols supplied about 15 crore liters of biofuel in FY25, amounting to ₹1,100 crore. * The blending program has progressed to nearly 20% in FY26, with discussions to increase it to 27%. * Government clarified the advantages of the blending program, including rural economy support and Forex savings of about ₹43,000 crore in FY25. * The company expects to see ethanol price softening in imports and domestic potentially.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.